DAHANCA 30 Et randomiseret non-inferiority studie af hypoxi-profilvejledt nimorazolbehandling i forbindelse med primær strålebehand-ling af planocellulære hoved-halskarcinomer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516178-31-00

Acronym

DAHANCA 30

Enrollment

1262

Registered

2024-11-29

Start date

2016-08-24

Completion date

Unknown

Last updated

2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinoma (HNSCC)

Brief summary

Locoregional control after radiotherapy (not including possible salvage treatment).

Detailed description

Local control (T-site), regional control (N-site), distant metastases, locoregional control after salvage treatment, overall survival (survival, disease- free survival, disease-specific survival), acute or late morbidity

Interventions

DRUGNimoral tablets 500 mg

DRUGCISPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Locoregional control after radiotherapy (not including possible salvage treatment).	—

Secondary

Measure	Time frame
Local control (T-site), regional control (N-site), distant metastases, locoregional control after salvage treatment, overall survival (survival, disease- free survival, disease-specific survival), acute or late morbidity	—

Countries

Denmark, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026